Drugs for Parkinson's Disease
Drugs for Parkinson's Disease
November 1, 2013 (Issue: 135)
The motor symptoms of Parkinson's disease (PD) are
caused primarily by progressive degeneration of
dopaminergic neurons in the substantia nigra. The non-motor
symptoms of the disease are thought to be caused
by degeneration of other...more
1. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drugs Ther 2005; 47:12.
2. R Schade et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29.
3. R Zanettini et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39.
4. JG Nutt and GF Wooten. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005; 353:1021.
5. KM Biglan et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69:187.
6. D Weintraub et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67:589.
7. V Voon et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 2011; 69:986.
8. HA Teive and RP Munhoz. Rotigotine-induced nail dyschromia in a patient with Parkinson's disease. Neurology 2011; 76:1605.
9. Apomorphine (Apokyn) for advanced Parkinson's disease. Med Lett Drugs Ther 2005; 47:7.
10. SZ Marsala et al. A systematic review of catechol-O-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 2012; 35:185.
11. Entacapone to Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 2007; 22:14.
12. Rasagiline (Azilect) for Parkinson's disease. Med Lett Drugs Ther 2006; 48:97.
13. LW Elmer. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord July 9, 2013 (epub).
14. CW Olanow et al. ADAGIO Study Investigators: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361:1268.
15. O Rascol et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365:947.
16. Deep brain stimulation for Parkinson's disease. Med Lett Drugs Ther 2013; 55:81.
17. MS Okun. Deep-brain stimulation for Parkinson's disease. N Engl J Med 2012; 367:1529.
18. KA Follett et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362:2077.
19. FM Weaver et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301:63.
20. WM Schuepach et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368:610.
21. M Menza et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72:886.
22. M Emre et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351:2509.
23. Drugs for cognitive loss and dementia. Treat Guidel Med Lett 2013; 11:95.
24. Memantine for Alzheimer's disease. Med Lett Drugs Ther 2003; 45:73.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Parkinson's Disease
Article code: 135a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
